

October 1, 2024

**COLUMBIA UNIVERSITY IRVING MEDICAL
CENTER POLICY RELATING TO THE USE AND
CONTROL OF INVESTIGATIONAL DRUGS FOR
INPATIENTS AT NEW YORK-PRESBYTERIAN
HOSPITAL**

POLICY:

This Columbia University Irving Medical Center (“CUIMC”) Policy outlines the standards for the storage, dispensing and administration of, and accountability for, investigational drugs administered to inpatients at New York-Presbyterian Hospital (“NYP”). Where applicable, this Policy is compliant with the NYP Policy on Use and Control of Investigational Drugs and other NYP policies relating to the storage, dispensing and administration of investigational drugs.

For purposes of this Policy, an “investigational drug” is defined as:

- Any drug not approved by the Food and Drug Administration (“FDA”) which is being studied under an Investigational New Drug Application (21 CFR 312) or a New Drug Application (21 CFR 314); and
- Any drug approved by the FDA which is central to the design of a research study, and not used in accordance with an approved label or package insert

This Policy is intended to comply with 21 CFR 312 (Investigational New Drug Application), 21 CFR 314 (Application for FDA Approval to Market a New Drug), New York State regulations, the requirements of the Joint Commission on Accreditation of Healthcare Organizations (the “Joint Commission”) and safe medication practice standards.

For investigational drugs used for outpatients, see the companion Policy, “Columbia University Irving Medical Center Policy Relating to the Use and Control of Investigational Drugs for Outpatients”.

APPLICABILITY:

This Policy applies to all Columbia University faculty and staff involved in the prescription, storage, dispensing and administration of, and accountability for, investigational drugs used in human subjects research at CUIMC.

PROCEDURES:

1. Any use of an investigational drug must be approved by the Columbia University Institutional Review Board, or another Institutional Review Board named in the CUIMC Federal Wide Assurance (in either case, an “IRB”). All research protocols using investigational drugs must contain the investigational drug information required to be provided in a Columbia University IRB submission. Such information must be reproducible and readily available to all CUIMC and NYP staff providing care to patients in a research study. All protocols that include commercially available drugs where NYP supplies will be used must be approved by the NYP Department of Pharmacy.

2. The principal investigator or a co-investigator or his/her IRB-approved designee will inform all study subjects or their legal representatives that the drug product being used is investigational. Except in exceptional circumstances, as approved by the IRB, informed consent of the subject or his/her legal

representative must be obtained prior to the use of an investigational drug.

3. The principal investigator and co-investigators should be identified in the IRB-approved protocol and the FDA Form 1572, if applicable.

4. All professionals involved in the storage, dispensing and administration of investigational drugs must hold active licenses in good standing with New York State, carry adequate personal medical liability insurance and adhere to CUIMC and NYPH credentialing requirements. When Schedule II – IV Controlled Substances are used in a research study, all investigators that prescribe such controlled substances must obtain a “Class 4 Researcher” License issued by the New York State Department of Health. The CUIMC Research Pharmacy (the “Research Pharmacy”) will be directed by a licensed pharmacist.

5. As required by federal regulations, the principal investigator is responsible for the handling and use of investigational drugs, provided that the principal investigator may delegate such responsibilities to the Research Pharmacy and certain individuals in accordance with the terms of this Policy.

6. All investigational drugs must be stored within the Research Pharmacy, or an area controlled by the Research Pharmacy where the investigational drug supplies are secured and stored separately from other drugs and supplies.

7. Only the principal investigator or a co-investigator may write an order for an investigational drug. Prior to dispensing any investigational drug, a complete medication order must be written, signed and made available in the patient’s medical record and NYP’s medication profiling system.

8. Once a medication order has been generated in accordance with NYPH policies, a pharmacist must review the order prior to the drug being dispensed and administered.

9. All investigational drugs must be dispensed either directly by the Research Pharmacy or from a Research Pharmacy-controlled automated dispensing cabinet. All dispensing procedures must be approved by the Research Pharmacy before study initiation.

10. Dispensed products must be labeled in accordance with Section 14 of this Policy and confirm with other applicable NYP labeling policies.

11. The following information must be made available for review by nurses and other hospital personnel prior to the administration of any investigational drug to an inpatient:

- Name of study protocol and protocol number assigned by the IRB;
- Name of the investigational drug and any synonyms;
- Principal investigator and co-investigator(s);
- Preparations (dosage form and strength) available from the Research Pharmacy;
- All pertinent data concerning the storage and preparation of the investigational drug (if the item is to be reconstituted, the specific diluents and procedure for dilution must be included and the subsequent stability of the reconstituted solution must be stated);
 - Dilution and compatibility data (e.g., intravenous fluid compatibility) applicable to parenteral or any extemporaneous preparations;
 - Method of administration;
 - Any special information related to administration;
 - Expected therapeutic effect and potential adverse effects (specific information related to

monitoring first dose response and longer-term effects should be included); and

- Any other important information relevant to the product.

12. The Research Pharmacy or the IRB will maintain systems that will make active study protocols relating to inpatients available for review by hospital staff pharmacists.

13. In all cases, the principal investigator is responsible for the proper maintenance of all investigational drug records required by the applicable sponsor, the IRB, the FDA, the Joint Commission and federal and state regulations. Product lot numbers and expiration dates must be recorded for each product dispensed, together with patient identifiers for the purpose of possible drug recalls.

14. All dispensed investigational drugs for inpatients must be labeled with, minimally, the following information:

- A distinctive label that states “For Investigational Use Only”
- Name of the drug
- Dosage form, strength and quantity
- Directions for use of the drug
- Patient’s name and medical record number
- Patient care unit
- Date dispensed
- Expiration time or date
- Initials of the individual dispensing the drug.

15. As an agent for the principal investigator, the Research Pharmacy will, pursuant to a written agreement, order, store, inventory, dispense and destroy or return to the sponsor all investigational drugs. Accountability records for all drug dispensing will be maintained for appropriate periods of time.

REFERENCES:

1. 21 CFR 312 (Investigational New Drug Application).
2. 21 CFR 314 (Application for FDA Approval to Market a New Drug).
3. Joint Commission on the Accreditation of Health Care Organizations, Accreditation Manual.
4. CFR Title 42, Volume 3, Chapter IV, Part 482.25, Conditions of Participation: Pharmaceutical Services.

POLICY DATES:

Issued: October 2008

Revised: October 2024

Reviewed: October 2024